Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study
| Autor: | Kim Hung Lo, S. Kafka, Philip J. Mease, Arthur Kavanaugh, Soumya D. Chakravarty, M. Elaine Husni, Elizabeth C. Hsia, L. Kim, D. Parenti |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
psoriatic arthritis
medicine.medical_specialty lcsh:Diseases of the musculoskeletal system business.industry Brief Report Arthritis Dermatology Life Quality Index psoriasis medicine.disease Placebo intravenous golimumab Golimumab humanities mNAPSI Psoriatic arthritis Rheumatology Psoriasis Area and Severity Index Internal medicine Rheumatoid arthritis Psoriasis Medicine lcsh:RC925-935 DLQI business medicine.drug |
| Zdroj: | ACR Open Rheumatology ACR Open Rheumatology, Vol 2, Iss 11, Pp 640-647 (2020) |
| ISSN: | 2578-5745 |
| Popis: | OBJECTIVE To evaluate whether intravenous (IV) golimumab produces improvements in skin and nail symptoms that are concomitant with improvements in quality of life (QoL) and joint symptoms in patients with psoriatic arthritis. METHODS Patients were randomized to either IV golimumab 2 mg/kg at weeks 0, 4, then every 8 weeks (q8w) through week 52 or placebo at weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg/kg at weeks 24, 28, and then q8w through week 52. Assessments included Psoriasis Area and Severity Index (PASI), modified Nail Psoriasis Severity Index (mNAPSI), Dermatology Life Quality Index (DLQI), and American College of Rheumatology (ACR) rheumatoid arthritis response criteria. RESULTS Through week 24, achievement of PASI 75/90/100 responses (P ≤ .0098) and mean improvements in mNAPSI (-11.4 vs -3.7; P < .0001) and DLQI (-9.8 vs -2.9; P < .0001) were significantly greater with golimumab versus placebo. Responses were maintained in patients treated with golimumab through week 52. In placebo-crossover patients, increases in the proportion of patients achieving PASI 75/90/100 responses were observed from weeks 24 to 52, and mean improvements in mNAPSI (from -3.7 to -12.9) and DLQI (from -2.9 to -7.8) increased from weeks 24 to 52. Simultaneous achievement of PASI and DLQI responses, PASI and ACR responses, and mNAPSI and DLQI responses were also observed. Similar responses were observed for all assessments regardless of concomitant methotrexate use. CONCLUSION Improvements in skin and nail psoriasis symptoms with IV golimumab in patients with psoriatic arthritis were concomitant with improvements in QoL and arthritis disease activity through 1 year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text